ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!BCEL Company Profile and Key Details
Atreca, Inc.
BCEL Stock Price Chart
Stock Price Today
Atreca, Inc. (BCEL) stock declined over -1.32%, trading at $0.09 on NASDAQ, down from the previous close of $0.09. The stock opened at $0.09, fluctuating between $0.09 and $0.09 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
Company Information
| Employees | 90 |
| Beta | 1.03 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Atreca, Inc. (NASDAQ: BCEL) stock price is $0.09 in the last trading session. During the trading session, BCEL stock reached the peak price of $0.09 while $0.09 was the lowest point it dropped to. The percentage change in BCEL stock occurred in the recent session was -1.32% while the dollar amount for the price change in BCEL stock was -$0.00.
The NASDAQ listed BCEL is part of Biotechnology industry that operates in the broader Healthcare sector. Atreca, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Herbert C. Cross
Chief Financial Officer
Ms. Courtney J. Phillips J.D.
Gen. Counsel & Corporation Sec.
Mr. John A. Orwin
Pres, Chief Executive Officer & Director
Dr. Stephen Gould Ph.D.
Chief Scientific Officer
Dr. Stephen E. Gould Ph.D.
Chief Scientific Officer
Dr. Yann Chong Tan
Chief Technologist
Dr. Tito A. Serafini Ph.D.
Founder, Chief Strategy Officer & Director
Dr. Philippe C. Bishop M.D.
Chief Medical Officer
Mr. John A. Orwin M.B.A.
Pres, Chief Executive Officer & Director
BCEL's closing price is 73.08% higher than its 52-week low of $0.05 where as its distance from 52-week high of $1.20 is -92.5%.
Number of BCEL employees currently stands at 90.
Official Website of BCEL is: https://www.atreca.com
BCEL could be contacted at phone 650 595 2595 and can also be accessed through its website. BCEL operates from 835 Industrial Road, South San Francisco, CA 94070, United States.
BCEL stock volume for the day was 122.12K shares. The average number of BCEL shares traded daily for last 3 months was 267K.
The market value of BCEL currently stands at $3.57M with its latest stock price at $0.09 and 39.65M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com